reports
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed...
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with im...
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Ru...
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 22,900 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise...
Glacier Bancorp, Inc. Announces First Quarter Earnings Release and Con...
Glacier Bancorp, Inc. Announces First Quarter Earnings Release and Conference Call KALISPELL, Mont., April 04, 2025 (GLOBE NEWSWIRE) -- Glacier Bancorp, Inc. (NYSE: GBCI) will report first quarter financial results after the market closes on April 24, 2025. A conference call for investors is scheduled for 11:00 a.m. Eastern Time on Friday, April 25, 2025. Please note that our conference call host no longer offers a general dial-in number. Investors who would like to join the call may now register by following this link to obtain dial-in instructions: To participate via the webca...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2025 (the “Grant Date”), ORIC granted a total of 50,600 non-qualified stock options and 8,250 restricted stock units to three new non-executive employees who began their employment with ORIC in March 2025. These inducement grants were gran...
Atlantic Petroleum – Update on Debt
Atlantic Petroleum – Update on Debt Tórshavn, Faroe Islands, 2025-04-04 (GLOBE NEWSWIRE) -- P/F Atlantic Petroleum (NASDAQ OMX: ATLA DKK) provides update on debt situation. Referring to the press release issued 31st March 2025 concerning debt negotiations, Atlantic Petroleum has come to a framework agreement with its main creditors whereby the total debt will be reduced by more than DKK 90 million. The debt reduction is subject to final agreements to be finalized. Part of the debt settlement includes London Oil and Gas (in administration) converting part of its debt to shares in Atlantic ...
Moody's Ratings assigns ratings to two classes of notes issued by Lake...
Moody's Ratings (Moody's) has assigned ratings to two classes of notes issued by Lake George Park CLO, Ltd. (the Issuer or Lake George Park CLO): U.S.$384,000,000 Class A Senior Secured Floating Rate Notes due 2038, Assigned Aaa (sf) U.S.$300,000 Class F Junior Secured Deferrable Floating Rate ...
Moody's Ratings assigns Ba3 rating to Owens & Minor's new senior secur...
Moody's Ratings (Moody's) assigned a Ba3 rating to Owens & Minor, Inc.'s ("Owens & Minor") proposed $1 billion senior secured notes. There are no changes to Owens & Minor's existing ratings including the Ba3 Corporate Family Rating (CFR), Ba3-PD Probability of Default Rating (PDR), Ba3 senior secure...
Edesa Biotech Announces Chief Financial Officer Transition
Edesa Biotech Announces Chief Financial Officer Transition TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy withi...
Moody's Ratings upgrades 11 ratings from GCAT 2022-INV1
Moody's Ratings (Moody's) has upgraded the ratings of 11 bonds from one transaction, backed by agency eligible non-owner occupied mortgage loans issued by GCAT 2022-INV1 Trust. Please click on this link /viewresearchdoc.aspx?docid=PBS_ARFTL505153 for the List of Affected Credit...
CubeSmart Announces the Date of Its First Quarter 2025 Earnings Releas...
CubeSmart Announces the Date of Its First Quarter 2025 Earnings Release and Conference Call MALVERN, Pa., April 04, 2025 (GLOBE NEWSWIRE) -- CubeSmart (NYSE: CUBE) today announced that the Company will release financial results for the three-month period ended March 31, 2025 after the market close on Thursday, May 1, 2025. An accompanying conference call will be held at 11:00 a.m. ET on Friday, May 2, 2025. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at investors.cubesmart.com. Telephone participants m...
CV Holdings, Inc. Update and Financial Statements for Year Ended Decem...
CV Holdings, Inc. Update and Financial Statements for Year Ended December 31, 2024 NEWPORT BEACH, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- CV Holdings, Inc. (OTC Pink Limited: CVHL) (the “Company”) today reported a net loss for the year ended December 31, 2024 of $(18,153,285) or $(0.28) per common share with weighted average common shares of 64,413,784 issued and outstanding during 2024. All outstanding warrants expired during 2024, and accordingly the net loss was also $(0.28) per diluted common share based on 64,413,784 common shares outstanding on a fully-diluted basis. The net loss...
National Bank Holdings Corporation Announces Date for 2025 First Quart...
National Bank Holdings Corporation Announces Date for 2025 First Quarter Earnings Release DENVER, April 04, 2025 (GLOBE NEWSWIRE) -- National Bank Holdings Corporation (NYSE: NBHC) expects to report its first quarter financial results after the markets close on Tuesday, April 22, 2025. Management will host a conference call to review the results at 11:00 a.m. Eastern Time on Wednesday, April 23, 2025. Interested parties may listen to this call by dialing (877) 400-0505 using the participant passcode of 7036929 and asking for the NBHC Q1 2025 Earnings Call. A recording of the call will be ...
Triumph Financial Announces Schedule for First Quarter 2025 Earnings R...
Triumph Financial Announces Schedule for First Quarter 2025 Earnings Release and Conference Call DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (Nasdaq: TFIN) today announced that it expects to release its first quarter financial results and management commentary after the market closes on Wednesday, April 16, 2025. Upon filing, the financial results and commentary will be available on the Company’s website at . Aaron P. Graft, Vice Chairman and CEO, and Brad Voss, CFO, will review the financial results in a conference call with investors and analysts beginning at 9:3...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing R...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2025, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 26,790 shares of its common stock, to o...
Wintrust Financial Corporation Announces Cash Dividends
Wintrust Financial Corporation Announces Cash Dividends ROSEMONT, Ill., April 04, 2025 (GLOBE NEWSWIRE) -- Wintrust Financial Corporation (“Wintrust” or the “Company”) (Nasdaq: WTFC) today announced that the Company’s Board of Directors approved a quarterly cash dividend of $0.50 per share of outstanding common stock. The dividend is payable on May 22, 2025 to shareholders of record as of May 8, 2025. Additionally, the Company’s Board of Directors approved quarterly cash dividends on outstanding shares of the Company’s 6.50% Fixed-to-Floating Non-Cumulative Perpetual Preferred Stock, Ser...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: ), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencemen...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Ru...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- , a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 5...
TEN Ltd. Declares Dividend on its Series F Cumulative Redeemable Perpe...
TEN Ltd. Declares Dividend on its Series F Cumulative Redeemable Perpetual Preferred Shares ATHENS, Greece, April 04, 2025 (GLOBE NEWSWIRE) -- TEN Ltd. (“TEN”) (NYSE: TEN) (the “Company”), a leading diversified crude, product and LNG tanker operator, today announced that its Board of Directors declared the regular quarterly cash dividend of approximately $0.59375 per share for its Series F Cumulative Redeemable Perpetual Preferred Shares (the “Series F Preferred Shares”; NYSE: TENPRF). The dividend on the Series F Preferred Shares is for the period from the most recent dividend payment...
NewtekOne, Inc. to Report First Quarter 2025 Results on Tuesday, May 6...
NewtekOne, Inc. to Report First Quarter 2025 Results on Tuesday, May 6, 2025 and Host a Conference Call on Wednesday, May 7, 2025 BOCA RATON, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) will report its first quarter 2025 financial results after the market closes on Tuesday, May 6, 2025. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer, M. Scott Price, Chief Financial Officer, and Frank DeMaria, Chief Accounting Officer, the following day, Wednesday, May 7, 2025, at 8:30 am ET. Please note, to receive a dial-in...
Artesian Water Company, Inc. Files Application with Delaware Public Se...
Artesian Water Company, Inc. Files Application with Delaware Public Service Commission for Increase in Customer Rates NEWARK, Del., April 04, 2025 (GLOBE NEWSWIRE) -- Artesian Water Company, Inc. (“Artesian”), a subsidiary of Artesian Resources Corporation (Nasdaq: ARTNA), filed an application with the Delaware Public Service Commission (PSC) today for a change in customer rates. The rate application submitted to the PSC for review and approval consists of a requested increase in revenue of 12.41%, or approximately $10.8 million, on an annualized basis. The increase also reflects the reco...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.